Loading...
  • prognostic
  • This work has confirmed LOH 1p/19q as a positive prognostic marker for oligodendroglioma and identified seven differentially expressed genes that, through their loss following LOH 1p/19q, could contribute to the development of oligodendroglioma or confer therapeutic sensitivity to the patient. (edu.au)
  • survival
  • Loss of heterozygosity (LOH) of the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q) is an early event in oligodendroglioma that occurs in up to 80% of patients and is associated with therapeutic sensitivity and longer overall survival. (edu.au)
  • Immunohistochemistry conducted on thirty grade III oligodendrogliomas demonstrated that protein staining scores for CHI3L1 and IQGAP1 were significantly higher in tumours without LOH 1p/19q, but found that IGF2, MIG-6 or PDPN were not suitable as markers for LOH 1p/19q or survival. (edu.au)
  • oncology
  • Oligodendroglioma - Pipeline Review, H1 2017, provides an overview of the Oligodendroglioma (Oncology) pipeline landscape. (medgadget.com)
  • Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oligodendroglioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Oligodendroglioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. (medgadget.com)
  • The Oligodendroglioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects. (medgadget.com)
  • Oligodendroglioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. (medgadget.com)
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Oligodendroglioma (Oncology). (medgadget.com)
  • The pipeline guide reviews pipeline therapeutics for Oligodendroglioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. (medgadget.com)
  • The pipeline guide reviews key companies involved in Oligodendroglioma (Oncology) therapeutics and enlists all their major and minor projects. (medgadget.com)
  • The pipeline guide evaluates Oligodendroglioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. (medgadget.com)
  • Find and recognize significant and varied types of therapeutics under development for Oligodendroglioma (Oncology). (medgadget.com)
  • Formulate corrective measures for pipeline projects by understanding Oligodendroglioma (Oncology) pipeline depth and focus of Indication therapeutics. (medgadget.com)
  • tumour
  • The purpose of this study was to confirm the reported association in patients at this centre, then identify and characterise genes that were differentially expressed and may function as a tumour suppressor or contribute to therapeutic sensitivity in oligodendroglioma. (edu.au)
  • Bisulfite sequencing, restriction analysis and qPCR confirmed PADI2 as a candidate tumour suppressor gene, methylated in oligodendrogliomas with LOH 1p/19q. (edu.au)
  • As no oligodendroglioma cell line with LOH 1p/19q was available, forty-six low grade tumour specimens were cultured to form primary cell lines. (edu.au)
  • Genes
  • Six candidate genes (CHI3L1, IGF2, IQGAP1, MIG-6, PDPN and PLAG1), which all showed significantly lower expression in oligodendrogliomas with LOH 1p/19q, were selected for further study. (edu.au)
  • Microarray analysis of DNA methylation in seven oligodendrogliomas with LOH 1p/19q (4 WHO grade II, 3 WHO grade III) identified DNA methylation of the PADI2 and ALX3 genes on chromosome 1p. (edu.au)
  • qPCR in forty--six oligodendroglioma specimens confirmed under-expression of each of the seven candidate genes in oligodendrogliomas with LOH 1p/19q. (edu.au)
  • grade
  • Seventeen oligodendroglioma specimens (5 WHO grade II with LOH 1p/19q, 2 WHO grade II without LOH, 5 WHO grade III with LOH 1p/19q, 5 WHO grade III without LOH) were examined by microarrays. (edu.au)